Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
about
Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportOlder patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.Chronic Myelogenous Leukemia (CML) in the elderlyImpact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.Age disparity in the dissemination of imatinib for treating chronic myeloid leukemiaAnalysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase.Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century.Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.Tyrosine kinase inhibitors in acute and chronic leukemias.Management options for refractory chronic myeloid leukemia: considerations for the elderly.First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Imatinib in chronic myeloid leukemia elderly patients.Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells.Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients.Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.
P2860
Q24800045-8EA746CB-CAC3-44DD-A695-5355F5DB1EE0Q33729437-E36D5CB1-5F26-4776-816A-48801583C816Q33778408-C6E4C85C-3A9C-4DED-BB73-33EDD8F5C675Q33890580-FF510532-8AB7-4819-8C53-AE86944343FCQ34032508-295EFDBA-A177-4A50-A844-7AC5AB15FD9DQ36094702-C3DC5862-3D40-404B-BC43-27239A86FB87Q36387433-0C9E0DD7-AE9F-4025-A111-D34318EAA1CAQ36533121-6671C49D-CA8B-441F-91F9-86DCD45B7D13Q37360066-A6E07454-4B55-4FED-A24F-8A91DB21D319Q37469835-8445270A-0ABC-4C75-850B-7EE938CF78EDQ38004075-C97D387B-30F8-4A8C-8DB6-1576E71EB51DQ38101471-A96446F3-BC1A-4E6F-A099-EBD306C0C608Q38202913-FFAC80EC-970A-4FD9-AAD5-FF754608E53EQ38216677-3AA87D5C-A6F8-4B78-AAFD-8B8AEEF2A472Q38767908-B216815E-963B-4D43-AB93-478BB643DCF4Q40346616-7851F490-4101-4C40-9E1E-75B025CAEA73Q43073098-27844BAB-C915-4851-9CE9-EFD807A91490Q44167290-44E1D5CF-8D1C-4F3B-9D9C-FD6021708899Q44695808-D2ACED19-4F62-42DD-9904-D19372759518Q44826305-344685DC-3406-4BBC-A040-14498219E774Q45007190-E03FCD63-C6BA-45BD-995B-8E22D9CCD1F3Q45988194-51956ABE-CE3E-4551-91FF-02D28C4705D3Q51309944-2BBD4C54-0D5C-42E9-9EF5-1801206AD776
P2860
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@en
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@nl
type
label
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@en
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@nl
prefLabel
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@en
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@nl
P50
P356
P1433
P1476
Effects of age on prognosis wi ...... chronic myelogenous leukemia.
@en
P2093
Jianquin Shan
Moshe Talpaz
P304
P356
10.1002/CNCR.11629
P407
P50
P577
2003-09-01T00:00:00Z